ABOUT R&D PIPELINE INVESTORS & MEDIA CAREERS An Open Letter from NGM Leadership on Standing Up to Bigotry, Racism and Prejudice ABOUT US Welcome to NGM Bio We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients. Our Team Board of Directors Scientific Advisory Board We are intensely science-driven and committed to having a profound impact on addressing some of today’s most urgent medical needs. We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that will enable us to move rapidly into proof-of-concept studies and deliver first-in-class medicines. We aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs already in clinical development. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. But we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines and building our proficiency in discovery research. Our Team Our management team, scientists, board members and advisors have extensive track records of successfully discovering, developing and delivering to patients multiple, class-defining drugs with meaningful clinical and commercial impact, which positions us well to maximize the potential of our drug discovery approach. William J. Rieflin Executive Chairman David J. Woodhouse, Ph.D. Chief Executive Officer Jin-Long Chen, Ph.D. Founder and Chief Scientific Officer Alex DePaoli, M.D. Senior Vice President, Chief Translational Officer Marc Learned, Ph.D. Vice President, Research Operations Hsiao D. Lieu, M.D. Senior Vice President, Chief Medical Officer Siobhan Nolan Mangini Chief Financial Officer Brian Muma Vice President, Human Resources Valerie Pierce Senior Vice President, General Counsel and Chief Compliance Officer Hui Tian, Ph.D. Senior Vice President, Research Board of Directors William J. Rieflin Executive Chairman, NGM Biopharmaceuticals David V. Goeddel, Ph.D. Managing Partner, The Column Group Jin-Long Chen, Ph.D. Founder and Chief Scientific Officer, NGM Biopharmaceuticals Shelly Guyer Chief Sustainability Officer, Invitae Corporation Carole Ho, M.D. Chief Medical Officer & Head of Development, Denali Therapeutics Suzanne Sawochka Hooper Former Executive Vice President and General Counsel, Jazz Pharmaceuticals Mark Leschly Managing Partner, RHO Capital Partners Roger M. Perlmutter, M.D., Ph.D. CEO, Eikon Therapeutics David J. Woodhouse, Ph.D. Chief Executive Officer, NGM Biopharmaceuticals Scientific Advisory Board Michael S. Brown, M.D. Chairman Michael Fischbach, Ph.D. Joseph L. Goldstein, M.D. Robert D. Schreiber, Ph.D. Special Advisors Grant Heidrich Arthur D. Levinson, Ph.D. © 2021 NGM Biopharmaceuticals. All Rights Reserved. Contact. Privacy Policy. Terms of Use.